85 results about "Ejection fraction" patented technology

The invention discloses a monitoring method and system and a related device, which are applied to first electronic equipment, the first electronic equipment is provided with a first circuit, and the first circuit comprises a first electrode, a second electrode, a third electrode, a fourth electrode, an excitation current generation unit and a voltage measurement unit; receiving and responding to a first instruction, and determining that the first electrode and the second electrode are in good contact with skin through a first circuit; first information is determined through the first circuit, the first electrode makes contact with a first position of the user skin, the second electrode makes contact with a second position of the user skin, and the first position and the second position are located at the two ends of the thoracic cavity tissue respectively; and outputting first information, wherein the first information comprises one or more of the following items: cardiac output, stroke output, heart rate, ejection fraction and cardiac function judgment result. Therefore, the heart function condition of the user can be monitored in real time, and the user can conveniently monitor anytime and anywhere.

The invention relates to the field of biomedicine, in particular to application of PXDC1 in preparation of a product for treating myocardial hypertrophy. The invention discloses the effectiveness of inhibiting PXDC1 expression in treating cardiac hypertrophy and controlling the occurrence and development process of the cardiac hypertrophy for the first time. The invention provides a novel drug target and strategy for treating myocardial hypertrophy, and the novel drug target and strategy can reduce the expression of a myocardial hypertrophy biomarker, reduce the size of myocardial cells, improve the ejection fraction and short axis shortening rate of the heart, reduce the weight ratio of the heart and relieve the degree of myocardial fibrosis. Besides, the invention clarifies the action mechanism of PXDC1 in myocardial hypertrophy, deepens the understanding of the pathogenesis of the disease, and lays an important foundation for further exploration of myocardial hypertrophy-related cytobiology and molecular biology processes.

The invention relates to the field of biological detection, in particular to application of IGSF1 protein as a cardiac function recovery marker. The invention provides application of protein as a marker in preparation of a product for detecting and / or diagnosing heart failure with improved ejection fraction. The protein comprises one or more of IGSF1, LIMS1, MPP1, PTX3, SLC2A3, FERMT3, ARPC1B, IGHG1, PTGS1, ACTN1 and RTN4, and is characterized in that the protein comprises one or more of the IGSF1, the LIMS1, the MPP1, the PTX3, the SLC2A3, the FERMT3, the ARPC1B, the IGHG1 The invention provides a novel serum marker, the expression level of the novel serum marker can predict heart failure patients with reduced ejection fraction and heart function recovery potential with high precision, and the change of the novel serum marker is earlier than the change of ejection fraction. According to the invention, a non-invasive standardized detection process based on a serum sample is established, all levels of medical institutions are adapted, and early and non-invasive prediction of the heart function recovery potential of the heart failure patient is realized.

The invention relates to the technical field of medical biology, and discloses an application of a biomarker in the diagnosis of ejection fraction retention type heart failure, and the biomarker is kynuric acid. The biomarker is applied to preparation of a product for diagnosing or predicting ejection fraction retention heart failure. According to the method, the ejection fraction retention heart failure can be diagnosed by quantitatively detecting the kynuric acid in the plasma.

The invention relates to the technical field of medical detection, in particular to application of a TTR tetramer in preparation of a product for diagnosing ejection fraction retention type heart failure. Experiments prove that in heart failure patients, TTR tetramers in HFpEF patients are obviously higher than those in non-HFpEF patients, and it is prompted that the TTR tetramers are related to HFpEF. According to the present invention, the diagnosis model and the kit using the TTR tetramer as the biomarker have good sensitivity and good specificity, can achieve the diagnosis or the auxiliary diagnosis, the treatment guidance and the prognosis of the HFpEF, and can improve the identification of different heart failure types such as the HFpEF and the non-HFpEF.

A method comprising is described herein comprising receiving first magnetic resonance imaging (MRI) data of a first plurality of subjects, wherein the first MRI image data comprises a first plurality of two-dimensional (2D) images, pre-processing the first MRI data for analysis, converting each two-dimensional image of the first plurality of 2D images into first tokens as input for a transformer encoder, wherein the transformer encoder comprises a time series classification transformer, training the transformer encoder using the first input tokens, receiving second MRI data of a subject, wherein the second MRI data comprises a second plurality of 2D images, converting each image of the second plurality of 2D images into second tokens as input to the trained transformer encoder, and applying the trained transformer encoder to the second tokens to predict a state of disease in a subject.